Opening https://www.globenewswire.com/news-release/2024/05/01/2873193/0/en/Denali-Therapeutics-Announces-Completion-of-Enrollment-for-Regimen-G-Evaluating-eIF2B-Agonist-DNL343-in-the-Phase-2-3-HEALEY-ALS-Platform-Trial.html